Pembrolizumab and Ramucirumab for Bladder Cancer

Phase 2

Waitlist Available

Led By Michael Hurwitz, PhD, MD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will study how well a combination of pembrolizumab and ramucirumab works in treating patients with TCC that has progressed after treatment with checkpoint inhibitors.

Eligible Conditions

Bladder Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Overall response rate (ORR)

Secondary study objectives

Overall survival (OS)

Progression free survival (PFS)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Pembrolizumab and RamucirumabExperimental Treatment1 Intervention

Patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor will receive Pembrolizumab and Ramucirumab.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor

1,924 Previous Clinical Trials

3,031,658 Total Patients Enrolled

Michael Hurwitz, PhD, MD5.01 ReviewsPrincipal Investigator - Assistant Professor of Medicine (Medical Oncology) Yale University

Yale University

5Patient Review

Dr. Hurwitz is an amazing oncologist who is both kind and brilliant. He talks to patients in a way that is easy to understand, and he is very patient. He is also very funny and professional.